Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Nerve Pain: later-stage trial registry

1 of 5 indexed Nerve Pain trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Nerve Pain: 5 US clinical trials tracked, 1 recruiting.

Nerve Pain is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 2 of these trials.

Enrollment posture brief

Registry condition nerve-pain

OPEN 1 | RECR 20% | LATE 2 | EARLY 0 | RANK #3391 | SPON 2

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Nerve Pain (this)20%
Open-enrollment share among volume-matched conditions near Nerve Pain

Nerve Pain lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nerve Pain on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nerve Pain is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Nerve Pain research.

    Dana-Farber Cancer Institute accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Nerve Pain trials plan to enrol fewer than 100 people.

    Median target enrolment is 44 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Nerve Pain research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Nerve Pain records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bupivacaine indwelling catheter Drug
1 trials
Liposomal bupivacaine injection Drug
1 trials
Education control Other
1 trials
Ultrasound Guided Approach Procedure
1 trials
Sham Acupuncture Other
1 trials
Electroacupuncture Other
1 trials
Pregabalin Drug
1 trials
Yoga Other
1 trials

US sites by state

Facility locations filed on Nerve Pain trials. A trial with sites in several states counts in each.

New York 2 trials
New Jersey 2 trials
Massachusetts 2 trials
Virginia 1 trials
Kansas 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nerve Pain page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nerve Pain condition card totals 5 registered trials; most-linked intervention Bupivacaine indwelling catheter; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.